- Home
- MUR vs SRRK Comparison
MUR vs SRRK Comparison
Compare MUR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | SRRK |
|---|---|---|
| Founded | 1950 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MUR | SRRK |
|---|---|---|
| Price | $34.01 | $43.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $29.29 | ★ $55.10 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 04-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $2,718,823,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.67 | $449.79 |
| P/E Ratio | $45.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.95 | $22.71 |
| 52 Week High | $36.08 | $49.82 |
Technical Indicators
Market Signals| Indicator | MUR | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 41.81 |
| Support Level | $29.81 | $41.54 |
| Resistance Level | $34.40 | $48.29 |
| Average True Range (ATR) | 1.39 | 2.21 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 65.03 | 18.96 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.